Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients

Launched by CORPORACION PARC TAULI · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new medical device that aims to help prevent a condition called oxaliplatin-induced peripheral neuropathy (OIPN) in patients with gastrointestinal cancer. OIPN can cause uncomfortable symptoms like tingling, numbness, or pain, which can occur after receiving chemotherapy treatment with a drug called oxaliplatin. The goal of the study is to gather information through interviews with patients who have experienced these symptoms, and use their feedback to help design a prototype of the device. This will not only focus on what patients need but also help prepare for future studies to test the device's safety and effectiveness.

To be eligible for this trial, participants must be adults over 18 who are currently outpatient cancer patients receiving oxaliplatin and have completed at least three cycles of chemotherapy. They should be experiencing symptoms of OIPN, whether new or ongoing. However, individuals with certain conditions such as arthritis or autoimmune diseases affecting connective tissue will not be included in the study. If you participate, you can expect to share your experiences and thoughts on how the device could be helpful, contributing to a solution that may improve the quality of life for many patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Outpatient patient with gastrointestinal cancer treated with oxaliplatin.
• • Having completed at least three cycles of chemotherapy.
• • Presenting acute or chronic symptoms of chemotherapy-induced peripheral neuropathy.
• • The study will include individuals over 18 years old. Gender identify will be collected confidentially and inclusively, offering options for non-binary individuals and those who prefer not to identify with binary categories.
• Exclusion Criteria:
• • Patient with osteoarthritis or arthritis in the hands.
• • Diagnosis of any autoimmune disease affecting connective tissue, such as: rheumatoid arthritis, Raynaud's syndrome, lupus, scleroderma, dermatomyositis, vasculitis, or cryoglobulinemia.